Phase I trial of weekly cabazitaxel with concurrent intensity modulated radiation therapy (IMRT) and androgen deprivation therapy (ADT) for the treatment of high-risk prostate cancer (PCa).

Authors

• William Kelly

Publication/Presentation Date

5-2014

Volume

32

Issue

15

Published In/Presented At

DOI: 10.1200/jco.2014.32.15_suppl.e16009

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article